Know
Rare
Endo

Welcome to
KnowRareEndo

Featuring clinical data on rare endocrine disorders, KnowRareEndo provides information and resources to help guide you in the identification, diagnosis and treatment of both Cushing’s disease and acromegaly.

7

Average time in years to a Cushing's disease diagnosis.1 Symptoms can vary greatly by patient, further complicating the path to diagnosis.2

Learn more

10-11

Estimated number of years acromegaly symptoms have been present, due to delay in diagnosis.3

Learn more
Cushing’s Disease
  • Prevalence 22 cases per million4,*
  • Annual New Cases 2.4 per million4,*

*True incidence and prevalence rates for CD in the United States are unknown. Estimated data are pooled rates based on a meta-analysis of global CD epidemiology.4

Cushing’s disease (CD) is a rare hormonal disorder caused by a pituitary adenoma that secretes excess adrenocorticotropic hormone (ACTH).5,6 Excess ACTH stimulates the adrenal glands to overproduce cortisol, leading to the clinical manifestations of CD.5

Acromegaly
  • Prevalence ≈25,0007
  • Annual New Cases 3,0007

Often referred to as somatotroph adenoma or growth hormone excess, acromegaly is a chronic metabolic disorder caused by the presence of too much growth hormone.8

Join our community of healthcare professionals interested in and dedicated to diagnosing and treating rare endocrine disorders.

REFERENCES: 1. Papoian V, Biller BMK, Webb SM, et al. Patients’ perception on clinical outcome and quality of life after a diagnosis of Cushing syndrome. Endocr Pract. 2016;22(1):51-67. doi:10.4158/EP15855.OR. 2. Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;17(7):281-293. doi:10.2147/CLEP. S44336. 3. Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. Eur J Endocrinol. 2018;14(2):57–61. doi: 10.17925/EE.2018.14.2.57. 4. Giuffrida G, Crisafulli S, Ferraù F, et al. Global Cushing’s disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022 Jun;45(6):1235-1246. doi: 10.1007/s40618-022-01754-1. 5. Geer EB, Shafiq I, Gordon MB, et al. Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study. Endocr Pract. 2017;23(8):962-970. doi: 10.4158/EP171787.OR. 6. Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277-2284. doi: 10.1210/jc.2012-3582. 7. Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH. Incidence and Prevalence of Acromegaly in the United States: A Claims-Based Analysis. Endocr Pract. 2016 Nov;22(11):1327-1335. doi: 10.4158/EP161397.OR. 8. What is Acromegaly? UCLA Health. Accessed August 23, 2022. https://www.uclahealth.org/medical-services/surgery/endocrine-surgery/patient-resources/patient-education/endocrine-surgery-encyclopedia/acromegaly.